DURHAM – Alcami Corporation, a contract development and manufacturing organization with a focus on pharmaceutical and biologic companies, has acquired Triangle startup TriPharm Services and its recently opened manufacturing center, just days after selling a plant in the Netherlands.
The Durham-based firm, which has an office in Wilmington and an operation in Charleston, S.C., has some 900 employees.
The deal for TriPharm was announced on Friday and involves capital infusion and some new ownership for Alcami. Financial terms were not disclosed.
Madison Dearborn Partners, the majority owner of Alcami, is putting more equity into the venture. And Ampersand Capital Partners, which helped fund the building of the TriPharm plant, is gaining an ownership share in Alcami, according to the announcement.
“Our combination with TriPharm is an important next step in the execution of Alcami’s strategy to focus investments across our network to better serve rapidly growing specialized market segments,” said Alcami Interim Chief Executive Officer George Van Kula. “TriPharm expands our existing capabilities and provides additional equipment lines that will allow us to better serve the fast-developing biologics market segment.”
TriPharm’s facility focuses on sterile fill-finish. It is expected to open in the second half of this year.
“As drug makers increasingly shift their focus toward more specialized, targeted therapeutics, and current injectable drug shortages hamper patient care, sterile fill-finish operations at proper scale are highly valued,” said TriPharm Co-Founder and Chief Executive Officer Patrick D. Walsh. “Our Research Triangle Park facility is designed to address this highly specialized industry demand.”
Earlier this month Alcami sold its preclinical and early stage active pharmaceutical ingredient (API) facility in Weert, Netherlands.
The buyers are MercachemSyncom, a leading mid-sized European integrated drug-discovery and development contract research organization.